Your browser doesn't support javascript.
loading
Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
Elkjaer, Maria L; Lohse, Rikke M; Burton, Mark; Mendoza, Jason P; Thomassen, Mads; Sejbaek, Tobias; Illes, Zsolt.
Afiliación
  • Elkjaer ML; Department of Neurology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, BRIDGE, University of Southern Denmark, Odense, Denmark; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. Electronic address: maria.louise.elkjaer@rsyd.dk.
  • Lohse RM; Department of Neurology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, BRIDGE, University of Southern Denmark, Odense, Denmark; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Burton M; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark; Clinical Genome Center, University of Southern Denmark & Region of Southern Denmark, Odense, Denmark; Human Genetics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Mendoza JP; Biogen, Cambridge, MA, USA.
  • Thomassen M; Department of Clinical Research, BRIDGE, University of Southern Denmark, Odense, Denmark; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark; Clinical Genome Center, University of Southern Denmark & Region of Southern Denmark, Odense, Denmark; Human Genetics, Department
  • Sejbaek T; Department of Neurology, Hospital of Southwest Jutland, Esbjerg, Denmark.
  • Illes Z; Department of Neurology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, BRIDGE, University of Southern Denmark, Odense, Denmark; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. Electronic address: zsolt.illes@rsyd.dk.
J Neuroimmunol ; 381: 578145, 2023 08 15.
Article en En | MEDLINE | ID: mdl-37393851
ABSTRACT
We investigated the impact of dimethyl fumarate (DMF), an oral therapy for relapsing multiple sclerosis (MS), on blood microRNA (miRNA) signatures and neurofilament light (NFL) levels. DMF normalized miR-660-5p and modulated various miRNAs associated with the NF-kB pathway. These alterations reached a peak 4-7 months after treatment. Notably, particular miRNAs correlated with high or low NFL levels, implying their potential role as markers of treatment efficacy. Our findings broaden the understanding of DMF's immunomodulatory effects and may aid in predicting treatment responses.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / MicroARNs / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Neuroimmunol Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / MicroARNs / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Neuroimmunol Año: 2023 Tipo del documento: Article